New Delhi, July 13
Drug agency Glenmark Pharmaceuticals on Monday mentioned it has discount of antiviral drug Favipiravir — bought underneath the model identify FabiFlu for the therapy of sufferers with gentle to average COVID-19 — by 27 per cent to Rs 75 per pill.
The firm had launched the drug final month at a value of Rs 103 per pill.
In a regulatory submitting Glenmark introduced a value discount of 27 per cent for FabiFlu. The new most retail value (MRP) is Rs 75 per pill, it mentioned.
“The price reduction has been made possible through benefits gained from higher yields and better scale, as both the active pharmaceutical ingredient (API) and formulations are made at Glenmark’s facilities in India, the benefits of which are being passed on to patients in the country,” the submitting mentioned.
The API is manufactured on the firm’s Ankleshwar plant, whereas the formulation is being manufactured at its Baddi plant in Himachal Pradesh.
“Our internal research shows us that we launched FabiFlu in India at the lowest market cost as compared to the cost of Favipiravir in other countries where it is approved. And now we hope that this further price reduction will make it even more accessible for patients across the country,” Glenmark Pharmaceuticals Senior Vice President and Head – India enterprise Alok Malik mentioned.
The firm additionally mentioned it has commenced a submit advertising surveillance (PMS) research on FabiFlu to carefully monitor the efficacy and security of the drug in 1,000 sufferers which might be prescribed with the oral antiviral, as a part of an open label, multicentre, single arm research, the submitting mentioned.
“We expect this post marketing surveillance study to shed more light on the drug’s clinical effectiveness and safety in a large cohort of patients prescribed FabiFlu,” Malik mentioned.
On June 20, Glenmark introduced receiving manufacturing and advertising approval from India’s drug regulator for FabiFlu, making it the primary oral Favipiravir-approved treatment in India for the therapy of gentle to average COVID-19.
The firm has additionally accomplished the section three medical trial with Favipiravir (FabiFlu) in gentle to average COVID-19 sufferers in India. The trial outcomes shall be out there shortly, the submitting mentioned.
Glenmark can be conducting one other Phase three medical trial to judge the efficacy of two antiviral medication Favipiravir and Umifenovir as a mixture remedy in average hospitalised grownup COVID-19 sufferers in India, it added.
When requested in regards to the firm’s manufacturing capability of the drug, Glenmark had earlier mentioned: “Considering a minimum of two strips per patient, Glenmark will be able to provide FabiFlu for about 82,500 patients in the 1st month itself. We will be closely monitoring the evolving situation and basis the situation, we will work to scale and meet the healthcare needs of the country.”
The nation noticed yet one more report single-day soar of 28,701 instances, pushing its tally to eight,78,254, whereas the loss of life toll climbed to 23,174, in response to the Union Health Ministry information at eight AM on Monday.
Shares of Glenmark Pharma closed at Rs 415.45 per scrip on the BSE, down 2.64 per cent from its earlier shut. — PTI